Hyunwoo Lee, Gyu Young Kim, Yoon Ah Cho, Gyungyub Gong, Hee Jin Lee, Byung-Kwan Jeong, Ji‐Seon Jeong, Young Kyung Bae, Min Chong Kim, So Yeon Park, Jiwon Koh, Jee Yeon Kim, Ho-Chang Lee, Hee Sung Kim, Wan Seop Kim, Young Hee Maeng, Sun Young Kwon, Chungyeul Kim, Sun-Young Jun, Hye Jeong Choi, Somang Lee, Nora Jee-Young Park, Ae Ri Ahn, Hyun Joo Choi, Jeong Yun Shim, Ji-Young Kim, Su Jung Kum, Hyang Im Lee, Song-Hee Han, Youjeong Seo, Yoon Jin Cha, Junjeong Choi, Yo Han Jeon, Ji Min Na, Miseon Lee, Hera Jung, Yeonjin Jeon, Jinye Yoo, Gui Young Kwon, Eun Yoon Cho, Ji Shin Lee
Received July 27, 2026 Accepted November 1, 2026 Published online November 2, 2026
Purpose
Accurate assessment of low levels of human epidermal growth factor receptor 2 (HER2) expression has become increasingly important with the expansion of HER2-targeted therapies to patients with HER2-low and HER2-ultralow breast cancer (BC). Following the introduction of revised College of American Pathologists (CAP) guidelines incorporating the HER2-ultralow (0+) category, we conducted a nationwide multireader study to evaluate interobserver variation in HER2 interpretation and to investigate the impact of artificial intelligence (AI)-assisted image analysis.
Materials and Methods
A total of 168 BC cases stained using the VENTANA HER2 (4B5) assay were digitized as whole-slide images (WSIs). Thirty-four board-certified breast pathologists independently reviewed all cases without AI assistance and repeated the assessment after a four-week washout period using AI support. Interobserver agreement, classification performance, and reading time were compared between the two phases.
Results
AI assistance significantly improved interobserver agreement (Krippendorff's alpha, 0.7415 to 0.8849; Fleiss' kappa, 0.4492 to 0.7524; p<0.001). The largest gains in diagnostic performance were observed in HER2-ultralow and HER2 IHC 1+ BCs, with sensitivities improving from 48.5% to 73.9% and from 64.9% to 87.7%, respectively (p<0.001). Although overall reading time was not reduced in the unadjusted analysis, AI assistance shortened interpretation time in HER2-ultralow BCs by 3.12 seconds (5.1% reduction).
Conclusion
AI-assisted assessment improved the reproducibility and diagnostic performance of HER2 interpretation, with the greatest benefit observed in clinically relevant HER2 low-expression categories. The reduced interpretation time in HER2-ultralow BCs further suggests that AI can improve efficiency in diagnostically challenging cases encountered in routine practice.
Purpose
Suicide risk is elevated among patients with cancer, but how clinician-documented suicidal ideation varies across time-updated TNM stages remains unclear. We examined this association after cancer diagnosis.
Materials and Methods
We conducted a retrospective cohort study of 134,369 patients using tumor registry and clinical records from Yonsei Cancer Center covering 2005–2021. We identified clinician-documented suicidal ideation using rule-based keyword screening and manual contextual review of electronic medical records. TNM stage was classified as CIS or stages I–IV and updated across eligible intervals. We estimated hazard ratios (HRs) using a marginal structural Cox model (MSM).
Results
During follow-up, clinician-documented suicidal ideation was recorded in 6,718 patients (5.0%). Compared with TNM stage I, adjusted HRs were 0.81 (95% CI, 0.61–1.07) for CIS, 1.36 (1.25–1.49) for stage II, 1.20 (1.11–1.31) for stage III, and 1.54 (1.43–1.67) for stage IV. The stage III estimate was lower than the stage II estimate.
Conclusion
Time-updated TNM stage was associated with clinician-documented suicidal ideation after cancer diagnosis, with the highest adjusted hazard observed for stage IV. These findings highlight the relevance of cancer-stage information to psychosocial assessment in cancer care.
Purpose
This study aimed to estimate the familial risk of biliary tract cancer (BTC) encompassing bile duct cancer (BDC) and gallbladder cancer (GBC) in offspring and to evaluate the interaction between family history and gallstones.
Materials and Methods
Korean National Health Insurance claims and Health Screening databases (2002–2018) were linked to create a cohort of 6,217,057 offspring and 3,655,642 parent couples from 1.4 million families. Incidence rate ratios (IRRs) and hazard ratios (HRs) compared BTC risk in offspring with versus without an affected parent. Interaction between family history and gallstones was assessed with the relative excess risk due to interaction (RERI). Subgroup analyses were stratified by age, sex, and residence in Clonorchis sinensis-endemic areas.
Results
Offspring with an affected parent had a 2.17-fold higher BTC risk than those without (0.35 vs. 0.08 cases per 10,000 person-years). Maternal history conferred greater risk than paternal history (HR 3.20 vs. 1.33). The IRR was higher in younger offspring. GBC or BDC risk in offspring was significantly associated with maternal, but not paternal, history of the other biliary cancer type, whereas no same-site associations were detected. Familial risk was lower in endemic than in non-endemic regions. Offspring with both gallstones and a family history showed markedly elevated risk (HR 17.36; 95% CI 9.80–30.81), although the interaction was not statistically significant (RERI 7.63; 95% CI -2.32–17.58).
Conclusion
Offspring with gallstones and a family history of BTC have more than a ten-fold increase in BTC risk. Early and intensive surveillance should be considered for this high-risk population.
Min Jung Kim, Kiho You, Jungnam Joo, Sung Chan Park, Dae Kyung Sohn, Hee Jin Chang, Dae Yong Kim, Hee Chul Park, Jae-Sung Kim, Byung Kwan Park, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Yong Beom Cho, Seong Hyeon Yun, Ji Won Park, Seung-Bum Ryoo, Seung-Yong Jeong, Hee Cheol Kim, Jae Hwan Oh
Received May 11, 2026 Accepted September 15, 2026 Published online September 16, 2026
Purpose
To evaluate the feasibility of local excision (LE) as an organ-preserving approach in patients with locally advanced rectal cancer showing a good response to neoadjuvant chemoradiotherapy (CRT).
Materials and Methods
This prospective, multicenter, single-arm phase II study enrolled patients with cT2–3N0–2M0 rectal adenocarcinoma downstaged to ycT0–1N0M0 after CRT. All patients underwent full-thickness LE. Patients with ypT0–1 were observed without completion total mesorectal excision (TME), whereas completion TME was recommended for those with ypT2–3 or positive margins. The primary endpoint was 3-year disease-free survival (DFS), with noninferiority defined as the lower bound of the one-sided 90% confidence interval (CI) exceeding 77.5%. The full analysis set (FAS) included all patients who underwent LE.
Results
Eighty patients were included [median follow-up, 74.2 months (Q1–Q3, 63.4–94.2)]. Pathology showed ypT0–1 in 62.5% and ypT2–3 in 37.5%. The 3-year DFS was 84.8% (lower 90% CI, 78.8%) in the FAS and 86.3% (lower 90% CI, 79.3%) in the per-protocol population. In the FAS, 5-year overall survival was 94.7%, and cumulative incidences of local recurrence (LR) and distant metastasis (DM) were 5.0%, and 8.9%, respectively. In subgroup analysis, 5-year DFS was 83.2% for ypT0–1, 88.9% for ypT2–3 with completion TME, and 75.3% for ypT2–3 without completion TME. The 30-day postoperative complications after transanal LE after CRT were 21.3%, and ≥ Clavien-Dindo grade 3 was 3.8%.
Conclusion
LE met the prespecified non-inferiority criterion for 3-year DFS with excellent local control in patients with ycT0-1 after neoadjuvant CRT. Transanal LE can be considered as an alternative organ-preserving strategy in selected patients with major response after CRT with acceptable postoperative complications, provided that appropriate surveillance is ensured.
Purpose East Asia has the highest gastric cancer incidence globally. Real-world treatment patterns and outcomes for human epidermal growth factor receptor 2 (HER2)–positive (HER2+) advanced gastric or gastroesophageal junction cancer (aGC/GEJC) remain poorly understood.
Materials and Methods This study enrolled adults with HER2+ aGC/GEJC diagnosed since January 2016 who received ≥ 2 lines of therapies (LOTs) with ≥ 6 months of follow-up across 31 centers in South Korea (KR), China (CN), Taiwan (TW), and Hong Kong (HK). Data were collected through November 2023. Treatment patterns, real-world efficacy outcomes, and adverse events of interest were analyzed descriptively.
Results Of 356 eligible patients (KR, 119; CN, 137; TW, 75; HK, 25), chemotherapy plus HER2-targeted monoclonal antibody was the most common 1st LOT regimen (61.0%), although utilization varied across countries/regions. Cross-country/region heterogeneity in treatment patterns emerged from the 2nd LOT onward. Median real-world overall survival varied across countries/regions (KR, 37.1; TW, 13.7; HK, 18.1 months); reliable survival estimation was precluded in CN due to ~50% loss to follow-up. Exploratory analyses suggested no survival benefit with trastuzumab use across multiple versus single LOT(s) (nominal p=0.96); however, sequential use of ≥ 2 HER2-targeted therapy types with distinct mechanisms of action (MoAs) may be associated with longer survival compared to a single type (nominal p=0.009).
Conclusion Cross-country/region heterogeneity in HER2+ aGC/GEJC treatment exists, likely driven by differential drug accessibility. Exploratory analyses suggested possible associations between HER2-targeted therapy and improved outcomes; however, inherent biases preclude causal inference. The sequential use of HER2-targeted therapies with distinct MoAs may be associated with clinical benefit, requiring prospective validation.
Purpose
Fecal immunochemical tests (FIT) are widely used for colorectal cancer (CRC) screening. This systematic review and meta-analysis evaluated the diagnostic accuracy of quantitative FIT for CRC and advanced neoplasm (AN), and examined variations in performance by sex, geographic region, study design, FIT platform, and positivity threshold.
Materials and Methods
A comprehensive search of MEDLINE, Embase, Cochrane Library, and KoreaMed was conducted. Studies evaluating the accuracy of quantitative FIT for CRC or AN using colonoscopy as a reference standard were included. The pooled sensitivity and specificity were estimated using a bivariate random-effects model. Meta-regression analysis was performed to analyze the diagnostic differences between sexes.
Results
Thirty-three studies were included. FIT showed higher sensitivity for CRC than for AN (78.6% vs. 32.3%), with high specificity for both outcomes (93.7% and 95.2%, respectively). Case-control studies yielded a significantly higher AN sensitivity than cohort studies (50.7% vs. 29.7%; p<0.05). Western studies showed significantly higher AN sensitivity and lower specificity than Eastern studies (31.6% vs. 24.2%, p<0.05; and 95.0% vs. 96.5%, p<0.05, respectively). In the sex-stratified analyses, males showed higher AN sensitivity than females (34.1% vs. 30.8%) and significantly lower CRC specificity (90.1% vs. 93.1%; p<0.05); however, the meta-regression showed no significant sex effect on the overall diagnostic accuracy for CRC or AN.
Conclusion
Quantitative FIT demonstrated strong performance for CRC detection but limited sensitivity for AN. Variations in the study design, FIT platform, threshold, region, and sex should be considered when interpreting FIT accuracy.
Purpose
Penile cancer is a rare malignancy. We aimed to update 5-year survival outcomes and cause of death in penile cancer using a nationally representative cohort dataset.
Materials and Methods
From the Cancer Public Library Database, we identified 415 men aged ≥30 years who were diagnosed with penile cancer between 2013 and 2019. Five-year overall survival (OS), cancer-specific survival (CSS), and relative survival (RS) were evaluated according to age at diagnosis, cancer stage, and primary treatment modalities. Causes of death in penile cancer were also examined according to the above variables.
Results
During a median follow-up of 2.9 years, 148 patients (35.7%) died. Five-year OS, CSS, and RS were 61.0%, 75.3% and 71.4%, respectively. Younger patients and those with localized stages exhibited more favorable survival. Patients treated with surgery alone had the highest survival. Among the 148 deaths, penile cancer accounted for 58.8%, followed by other cancers (18.9%). Non-penile cancer deaths predominated in older patients and those with localized stages.
Conclusion
Five-year survival outcomes for penile cancer in Korea were comparable to those reported in Western countries and remained largely unchanged from historical estimates. Age, stage, and treatment modality were strong determinants of survival. Older patients and those diagnosed with localized disease more frequently died from causes other than penile cancer itself, highlighting the importance of comprehensive survivorship care and consideration of overall health status and comorbidity burden beyond oncologic surveillance.
Purpose
To characterize trends and structural patterns in government-funded cancer research and development (R&D) in South Korea using National Science & Technology Information Service (NTIS) records.
Materials and Methods
We analyzed all NTIS projects during 2006–2024 (n=519,618), extracted via the NTIS OpenAPI. A bilingual regular-expression lexicon applied to Korean and English titles and keywords classified projects as definite (C2), possibly (C1), or unrelated (C0) to cancer, validated by two independent physicians on stratified samples. Outcomes included annual cancer-related project counts and funding, research-stage composition, and keyword dynamics.
Results
The lexicon identified 18,833 definite and 381 possible cancer-related projects, with high validated accuracy (κ=0.997). Cancer-related projects rose from 905 in 2006 (2.85% of NTIS projects) to a peak of 4,008 in 2021 (5.42%) and then plateaued (3,753 in 2023). In 2024, amid a government-wide R&D reduction, counts declined to 3,386 (5.67%), though cancer-related R&D was relatively protected as its NTIS share rose. Funding peaked at approximately 673 billion KRW in 2023 (1.9%–3.3% of annual government R&D). Basic research accounted for 71.7% of projects, whereas funding was more evenly distributed (basic 51.4%, development 23.0%, applied 17.5%). Keywords shifted from anticancer drugs and metastasis toward microenvironment, biomarkers, immunotherapy, liquid biopsy, organoids, and artificial intelligence.
Conclusion
Government-funded cancer R&D in South Korea expanded through 2021 and was subsequently sustained—including relative protection during the 2024 government-wide R&D reduction—while retaining a basic-research backbone and shifting toward precision- and data-intensive oncology. NTIS-based monitoring may help guide strategic allocation of public cancer R&D.
Se-Il Go, Jinyong Kim, Sehhoon Park, Il Hwan Kim, Dong-Wan Kim, Yun-Gyoo Lee, Jang Ho Cho, Eun Kyung Cho, Hyun Woo Lee, Ji-Hyun Park, Eun Joo Kang, Youngjoo Lee, Nak-Hoon Son, So Hyeon Gwon, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Gyeong-Won Lee
Received June 7, 2026 Accepted August 7, 2026 Published online August 10, 2026
Purpose
We assessed whether baseline and early on-treatment measurements of host fitness using the Prognostic Nutritional Index (PNI) provide complementary prognostic information in advanced non-small cell lung cancer (NSCLC).
Materials and Methods
Within the prospective, multicenter OPTIMUS trial, 497 patients with advanced NSCLC receiving first-line pembrolizumab-based therapy were analyzed. PNI was calculated from serum albumin and lymphocyte count at baseline and before cycle 2 (early on-treatment). Using a cutoff of 50.5, 441 patients with paired measurements were classified by baseline/early on-treatment PNI status as high/high, high/low, low/high, or low/low.
Results
Low baseline PNI was associated with lower objective response and higher treatment-related mortality. Among responders, low early on-treatment PNI was associated with lower odds of 6-month response maintenance (adjusted OR, 0.40; 95% CI, 0.17–0.97). Response-maintenance rates were lowest in the low/low group at both 6 and 12 months. In multivariable analyses including both PNI time points, low early on-treatment PNI was associated with shorter PFS (HR, 1.50; 95% CI, 1.11–2.04), whereas low baseline PNI was not (HR, 1.27; 95% CI, 0.94–1.71). Both low baseline PNI (HR, 1.53; 95% CI, 1.07–2.19) and low early on-treatment PNI (HR, 1.47; 95% CI, 1.02–2.12) were associated with shorter OS. The higher mortality risk in the low/low group was generally consistent across PD-L1 expression and treatment regimen subgroups.
Conclusion
PNI assessment at baseline and before cycle 2 provides complementary prognostic information, with early on-treatment PNI particularly related to PFS and response durability (ClinicalTrials.gov Identifier: NCT04909164).
Purpose This study aimed to determine the association between metabolic syndrome (MetS) and lung cancer risk in a large population-based cohort of never-smokers in Korea.
Materials and Methods Using the Korean National Health Insurance Service database, we identified adults who underwent national health screening in 2009 and consistently reported their never-smoker status at baseline and subsequent examinations. Cox proportional hazards models were used to estimate hazard ratios (HRs) for lung cancer incidence, adjusting for age, sex, body mass index (BMI), physical activity, residential area, income, and alcohol consumption. Analyses were further stratified according to sex and BMI.
Results Overall, 2,721,804 never-smokers were followed up for a mean of 14.0 years. The incidence of lung cancer was higher among participants with MetS than those without (adjusted HR, 1.04; 95% confidence interval [CI], 1.01 to 1.07). MetS was significantly associated with lung cancer risk in men (HR, 1.18; 95% CI, 1.11 to 1.25) but not in women (HR, 1.03; 95% CI, 0.99 to 1.07), with the risk evident in normal-weight and pre-obese men but, in women, mainly in those with obesity (HR, 1.10; 95% CI, 1.03 to 1.16).
Conclusion MetS was associated with a modest increase in the risk of lung cancer among Korean never-smokers, showing a significant association among men but not women. MetS risk was evident even among normal-weight men, whereas among women, it was more pronounced in those with obesity. These findings suggest that metabolic abnormalities, relatively underrecognized as cancer-related risk factors, could contribute to the risk of lung cancer, even in the absence of tobacco exposure.
Purpose
The outcomes of different antidiarrheal strategies in HER2-positive breast cancer patients treated with pyrotinib plus trastuzumab and docetaxel are unknown.
Materials and Methods
97 eligible patients received pyrotinib once daily from Cycle 1 Day 7 onwards, combined with intravenous trastuzumab and docetaxel on Day 1 of each 21-day cycle. In the 400PYR cohort, patients were treated with 400 mg pyrotinib, without mandatory antidiarrheal prophylaxis. In the 320PYR+Pro-L and 400PYR+Pro-L cohorts, patients were given 320 or 400 mg pyrotinib and loperamide prophylaxis. In the 320PYR cohort, patients were treated with 320 mg pyrotinib, without mandatory antidiarrheal prophylaxis. In the PYR-DE+Pro-L cohort, patients were treated with escalating pyrotinib doses and loperamide prophylaxis.
Results
The incidence of grade 3 diarrhea in cohorts with loperamide prophylaxis was lower than in the 400PYR cohort. In the 3 cohorts with loperamide prophylaxis, the dose escalation cohort had the lowest incidence of grade 3 diarrhea. The incidence of grade 3 diarrhea in 320PYR cohort was similar to the 3 cohorts with prophylactic antidiarrheal loperamide. No event of grade 4 or 5 diarrhea was reported.
Conclusion
Loperamide prophylaxis and pyrotinib dose escalation were associated with lower observed rates of grade 3 diarrhea in patients receiving pyrotinib plus trastuzumab and docetaxel. The lower rate observed in the 320PYR cohort should be interpreted cautiously and may reflect improved clinical management rather than a reproducible protocolized intervention.
Jun-Ha Jang, Jong Eun Park, Jung Won Chun, Hyeji Kim, Jinhyuk Bhin, Junghyeok Lim, Sang Myung Woo, Joo Kyung Park, Dae Wook Hwang, Sung-Sik Han, Woo Jin Lee, Dong-Eun Lee, Sang-Jae Park, Sun-Young Kong
Received April 30, 2026 Accepted July 20, 2026 Published online July 21, 2026
Purpose
This study aimed to identify germline pathogenic/likely pathogenic variants in DNA damage repair genes associated with increased cancer risk in Korean patients with biliary tract cancer and characterize their population-specific patterns.
Materials and Methods
In this retrospective multicenter cohort study, we performed germline whole-exome sequencing in 172 Korean patients diagnosed with intrahepatic cholangiocarcinoma (n = 83) or gallbladder cancer (n = 89) between June 2001 and February 2022. Germline variants were analyzed in 210 hereditary cancer genes, and the germline landscape of this cohort was compared with that of global cohorts.
Results
Pathogenic/likely pathogenic variants were identified in 24 of 172 (14.0%) patients, predominantly in DNA damage repair genes (18 of 24 [75.0%]). BRCA2 was among the most frequently altered genes, harboring two distinct pathogenic variants (2 of 24 [8.3%]; both cases of intrahepatic cholangiocarcinoma). Of the 24 carriers, five (20.8%) harbored Tier 1–2 variants of potential, tumor-confirmation-dependent therapeutic relevance. Notably, 15 of 24 (62.5%) carriers reported no family cancer history. In population-stratified comparisons across nine biliary tract cancer cohorts (n = 4,018), PMS2 showed a Korean-enriched signal after accounting for heterogeneous gene coverage, whereas TP53 showed only a directional, non-significant increase after multiple-testing correction.
Conclusion
The study findings provide reference data for genetic counseling in East Asian patients with biliary tract cancer and suggest that germline testing may warrant consideration regardless of family history.
Purpose
Breast cancer (BRCA) is a heterogeneous disease with a complex etiology. The prognostic value of genes related to migrasomes and the tumor microenvironment (MTMERGs) in BRCA is unclear.
Materials and Methods
A prognostic risk model was constructed using six core signature genes identified from MTMERGs via differential expression analysis and Cox regression. Its reliability was validated in an independent cohort using Kaplan-Meier and time-dependent ROC curves. A nomogram was developed and assessed via Decision Curve Analysis (DCA). Biological functions and immune infiltration were evaluated with GSEA, CIBERSORT, and ssGSEA. Immunotherapy sensitivity was predicted using TIDE/IPS scores and the IMvigor210 cohort. Tumor Mutation Burden (TMB) analysis and the pRRophetic algorithm were used for further clinical correlation and drug sensitivity prediction.
Results
The six-MTMERG model effectively stratified patients into high- and low-risk groups with distinct survival outcomes. The high-risk group was associated with a predicted immunosuppressive microenvironment (estimated enrichment of M0/M2 macrophages), higher TMB, and poorer prognosis. In contrast, the low-risk group was estimated to possess an immunologically active profile and showed a better predicted response to immune checkpoint inhibitors. Predicted differential sensitivities to conventional chemotherapy were also computationally evaluated between the subgroups.
Conclusion
We developed a computationally derived and externally validated prognostic model for BRCA based on migrasome and tumor microenvironment features. It successfully stratifies patients into groups with divergent clinical outcomes, immune profiles, and therapeutic responses, providing insights into BRCA heterogeneity and prognosis. Further prospective and experimental validation is warranted before clinical application.
Purpose
Identifying nonresponders to atezolizumab plus bevacizumab (AB) remains challenging in unresectable hepatocellular carcinoma (uHCC). We aimed to develop and externally validate a simple risk scoring system using baseline neutrophil-to-lymphocyte ratio (NLR) and extrahepatic spread (EHS) to predict treatment outcomes.
Materials and Methods
We included 304 patients with uHCC receiving first-line AB from multiple Korean centers (discovery, n = 220; validation, n = 84). Study outcomes included objective response rate (ORR) assessed by modified Response Evaluation Criteria in Solid Tumors, overall survival (OS), and progression-free survival (PFS). Multivariable analysis identified high NLR (>4.575) and EHS as independent predictors of nonresponse. The NLR-EHS score assigned 2 points for high NLR and 1 point for EHS (range, 0–3).
Results
In the discovery cohort, the score predicted nonresponse with an area under the receiver operating characteristic curve (AUC) of 0.749 (95% CI, 0.688–0.810); ORR fell across low- (0), moderate- (1–2), and high-risk (3) groups (67.3%, 47.7%, and 8.2%; p < 0.001). Validation confirmed comparable discrimination (AUC, 0.705; 95% CI, 0.603–0.806) and a consistent ORR gradient (77.8%, 54.2%, and 22.2%; p < 0.001). The score was prognostic for OS in discovery (HR, 1.28; p = 0.003) and validation cohorts (HR, 1.45; p = 0.007), remaining significant after adjustment (adjusted HR, 1.25 and 1.61, respectively). High-risk patients had inferior median OS (6.9 vs. 17.1 months in validation).
Conclusion
The NLR-EHS score is a practical tool for stratifying nonresponse risk and survival in uHCC patients receiving AB, facilitating early identification of high-risk patients who may benefit from alternative strategies.
Purpose Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by heterogeneous multisystem manifestations and frequent MAPK-ERK pathway alterations. Data on the clinico-pathologic features and real-world outcomes of adult ECD in South Korea are limited.
Materials and Methods We conducted a retrospective multicenter cohort study of adult patients (≥ 18 years) with ECD at seven Korean Cancer Study Group (KCSG)–affiliated institutions between October 2008 and June 2024. Clinical and pathologic features, BRAF V600E mutation status, treatment patterns, and overall survival (OS) were analyzed using the Kaplan-Meier method.
Results Twenty-two patients were included (median age, 57 years; interquartile range [IQR], 45 to 64; 50% male). Organ involvement was heterogeneous: bone (54.5%), retroperitoneal/renal (31.8%), central nervous system (27.3%), cardiovascular (27.3%), hypothalamic-pituitary axis (27.3%), pulmonary (18.2%), and skin (13.6%); multisystem disease (≥ 2 organs) was present in 40.9%. BRAF V600E was positive in 11 of 19 tested patients (57.9%). Treatment was initiated in 18 patients (81.8%); interferon-α–based regimens were the most common first-line approach (50.0%). Among 16 evaluable patients, the disease control rate (complete response/partial response/stable disease) was 87.5%. With a median follow-up of 4.6 years (IQR, 1.3 to 6.5), 2- and 5-year OS rates were 90.0% and 74.3%, respectively.
Conclusion Korean adult patients with ECD demonstrate heterogeneous organ involvement and frequent BRAF V600E positivity. Real-world treatment remains dominated by interferon-α–based approaches, underscoring the need for standardized molecular testing and improved access to targeted therapy.
Purpose Preclinical studies suggest that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) may have cancer-preventive effects; however, clinical evidence remains inconclusive. Therefore, this study aimed to evaluate the association between the use of SGLT-2is (empagliflozin or dapagliflozin) and the incidence of new-onset cancer in patients with type 2 diabetes.
Materials and Methods This nationwide retrospective cohort study used Korean national health claims data. Patients with type 2 diabetes who started empagliflozin, dapagliflozin, or other glucose-lowering drugs (oGLDs) between 2016 and 2019 were included, and propensity score matching between SGLT-2is users and oGLDs users was applied. The primary outcome was overall cancer incidence, and the secondary outcomes were the incidence of 11 site-specific cancers. Hazard ratios (HRs) and confidence intervals (CIs) for cancer incidence adjusted for covariates were estimated using a Cox proportional hazards model.
Results After propensity score matching, each group comprised 20,456 patients. There was no significant difference in the overall incidence of new-onset cancer in either the empagliflozin or dapagliflozin groups when compared to the oGLDs user group (adjusted HR, 0.85; 95% CI, 0.65 to 1.12; adjusted HR, 0.87; 95% CI, 0.66 to 1.14, respectively). Similar results were observed in site-specific cancer incidence. Furthermore, there were no significant differences in overall or site-specific cancer incidence between the empagliflozin and dapagliflozin user groups. The results were consistent across subgroup analyses and various sensitivity analyses.
Conclusion In this large-scale national cohort study, the use of empagliflozin or dapagliflozin did not show a significant difference in the incidence of new-onset cancer in patients with type 2 diabetes. These results provide insights into the association between SGLT-2i use and cancer risk in this population, based on real-world clinical data. Longer-term follow-up studies would be helpful in strengthening the validity of these findings.
Purpose This study evaluated the comparative clinical effectiveness and cost-effectiveness of robot-assisted minimally invasive esophagectomy (RAMIE) versus open esophagectomy (OE) and conventional minimally invasive esophagectomy (MIE) in a nationwide real-world setting.
Materials and Methods A target trial emulation was conducted using the Korean National Health Insurance Service database, including patients who underwent first-time esophagectomy for esophageal cancer between 2010 and 2023, with survival followed through June 2024. Propensity score–matched cohorts were created for RAMIE versus OE (n=1,713 per group) and RAMIE versus MIE (n=1,162 per group). Clinical outcomes were compared, and a 5-year semi-Markov model was used to estimate quality-adjusted life-years (QALYs) and costs from a healthcare sector perspective with a 4.5% annual discount rate. Incremental cost-effectiveness ratios (ICERs), incremental net benefits (INBs), and probabilistic sensitivity analyses were calculated.
Results RAMIE showed comparable or better short-term outcomes, including lower incidence of transfusion-requiring bleeding risk than OE (23.6% vs. 32.5%; relative risk [RR], 0.73; 95% confidence interval [CI], 0.65 to 0.81) and MIE (27.9% vs. 33.6%; RR, 0.88; 95% CI, 0.77 to 0.99). Long-term survival was superior to OE (hazard ratio [HR], 0.80; 95% CI, 0.72 to 0.88) and similar to MIE (HR, 0.93; 95% CI, 0.82 to 1.06). RAMIE yielded higher QALYs (Δ0.311 vs. OE; Δ0.126 vs. MIE) and lower 5-year costs ($12,372-$19,765 vs. OE; $1,703-$9,097 vs. MIE), resulting in negative ICERs, positive INBs, and high probabilities of costeffectiveness in sensitivity analyses.
Conclusion RAMIE showed a favorable clinical and cost-effectiveness profile compared with OE and MIE, adding to the evidence base for its broader adoption.
Young-Woong Won, Sun Young Rha, Jung Hye Kwon, Yu Jung Kim, Shin Hye Yoo, Myung Ah Lee, Jung Hun Kang, Sun Jin Sym, Young Saing Kim, Sang-Cheol Lee, Myung-Won Lee, Hye Sook Han, Sang-Gon Park, Eun-Kee Song, Jin Young Kim, Seong Hoon Shin, Chi Hoon Maeng, Keun Seok Lee, Hyun Woo Lee, Woo Kyun Bae, Kyu-Hyoung Lim, Yoon Jung Chang, Han Byul Lee, Jung Sun Kim
Received November 18, 2025 Accepted June 7, 2026 Published online June 11, 2026
Purpose This study aimed to assess the awareness, perception, and utilization of complementary and alternative medicine (CAM) among Korean patients with cancer and their caregivers. Furthermore, it evaluated CAM information sources, the reliability of these sources, communication patterns with clinicians, and the effect of caregiver beliefs on the use of CAM and patients’ attitudes toward CAM.
Materials and Methods A nationwide cross-sectional survey was conducted from September 2021 to January 2022 across 19 hospitals in South Korea. Adult patients with cancer and their accompanying caregivers were recruited via convenience sampling from outpatient oncology clinics and inpatient settings and completed a structured questionnaire. Data from 1,804 patients and 768 family members were analyzed using descriptive statistics and appropriate comparative tests.
Results Among patients, 47.2% had heard of CAM, and 41.0% expressed belief in it. Biologically based therapies were the most commonly used form of CAM among users (55.0%). The primary sources of CAM information were family/relatives (24.8%) and television (23.8%), whereas medical professionals accounted for only 5.4% of sources, although doctors and nurses were perceived as the most reliable (mean reliability: 3.43 on a 5-point scale). A significant communication gap was observed, with 71.7% of patients not discussing CAM with their medical professionals. Common reasons for non-disclosure included a lack of patient interest (39.4% of non-disclosers), the perception that CAM was irrelevant to their doctors (27.6%), and concerns about physician disapproval. Among patients who did consult their clinicians, 60.8% were advised against CAM use. Caregivers’ CAM beliefs significantly influenced patients’ beliefs (odds ratio [OR], 4.242; p < 0.001), although this did not translate into a statistically significant direct effect on CAM use by patients (OR, 1.449; p=0.105).
Conclusion CAM awareness and use are substantial among Korean patients with cancer; however, a critical communication gap with healthcare providers persists. Family members are key information sources, and caregiver beliefs influence patient beliefs regarding CAM. Proactive, empathetic, and evidence-based communication about CAM is essential to promote shared decision-making and ensure safe, patient-centered integrative cancer care.
Purpose Despite a nationwide breast cancer screening program in Korea, spatial disparities in stage at diagnosis persist. This study aimed to examine disparities in breast cancer incidence by stage and their association with area-level risk factors.
Materials and Methods We conducted a population-based ecological study using data from the Korea National Cancer Incidence Database (2005-2018). Among 230,214 women diagnosed with breast cancer, 215,803 with known stage were included. Stage-specific incidence across 250 municipalities was estimated for three periods (2005-2008, 2009-2013, and 2014-2018). For 2014-2018, associations with the area deprivation index (ADI), obesity rate, alcohol consumption rate, cancer screening rate, and mammography unit availability were assessed using Bayesian hierarchical models.
Results Of 215,803 patients, 59.0% had localized-stage disease, 35.5% regional-stage disease, and 5.5% distant-stage disease. Localized-stage incidence was higher in affluent areas, whereas distant-stage incidence was higher in deprived areas. In multivariable models, lower ADI (β=–0.058; 95% credible interval [CrI], –0.098 to –0.019), lower obesity rate (β=–0.066; 95% CrI, –0.091 to –0.041), and higher mammography availability (β=0.014; 95% CrI, 0.001 to 0.027) were significantly associated with higher localized-stage incidence. Conversely, higher ADI (β=0.103; 95% CrI, 0.017 to 0.188) and higher alcohol consumption (β=0.227; 95% CrI, 0.115 to 0.338) were significantly associated with increased distant-stage incidence.
Conclusion Spatial disparities in stage-specific breast cancer incidence in Korea were associated with area-level deprivation, health-care resources, and health-related behaviors. Integrating spatial perspectives into cancer control strategies may help promote more equitable early detection and contribute to improving breast cancer outcomes.
Purpose Genome-wide association studies (GWASs) have identified single-nucleotide polymorphisms (SNPs) at the 6p21.1 locus associated with gastric cancer (GC) risk. However, the underlying biological mechanisms remain poorly understood.
Materials and Methods We conducted fine-mapping analysis of the 6p21.1 region using large-scale GC GWAS data (10,254 cases and 10,914 controls). Functional annotation, luciferase reporter assays, electrophoretic mobility shift assay, and chromatin immunoprecipitation experiments were performed to identify functional variants. The expression quantitative trait loci and colocalization analyses were used to determine the susceptibility gene. Mechanistic investigations included phenotypic assays under normoxic and hypoxic conditions, along with Seahorse, immunofluorescence, and ATP assays to assess mitochondrial function.
Results We identified rs9381024 as the independent association signal at 6p21.1, with rs2235679, in strong linkage disequilibrium with rs9381024, emerging as a potential causative SNP. The T risk allele of rs2235679 reduced APOBEC2 expression by enhancing the binding of transcriptional repressor MZF1, thereby suppressing promoter activity. Expression analysis revealed a progressive decrease in APOBEC2 levels with gastric lesion severity, becoming nearly undetectable in GC tissues. Functionally, reduced APOBEC2 expression significantly promoted the proliferation of GC cells under hypoxic conditions but not under normoxia. Mechanistically, downregulation of APOBEC2 activated mitophagy to maintain mitochondrial homeostasis via the hypoxia-inducible factor-1α/BNIP3 pathway under hypoxia, ultimately driving tumor growth.
Conclusion Our findings provide novel mechanistic insights into how genetic variants at 6p21.1 contribute to GC risk and progression, highlighting the tumor-suppressive role of APOBEC2.
Purpose In breast cancer (BC) patients without pathological complete response (pCR) after neoadjuvant therapy, residual disease drives recurrence. The human epidermal growth factor receptor 2 (HER2) spectrum now includes HER2-low and HER2-ultralow. HER2-low tumors are eligible for HER2-targeted antibody-drug conjugates (ADCs), while trastuzumab deruxtecan is approved for hormone receptor–positive HER2-ultralow metastatic BC after endocrine therapy. Evolution patterns of HER2-ultralow versus HER2-null from residual to metastatic disease remain unclear.
Materials and Methods We retrospectively studied 488 non-pCR patients with refined HER2 classification; 92 with HER2-0 residual disease formed the analytic cohort for HER2-ultralow/HER2-null comparison. HER2 status was tested in paired residual and metastatic lesions. Logistic regression was used to identify factors linked to HER2 evolution.
Results In the 92‑patient HER2‑0 analytic cohort, HER2-ultralow (46.7% of HER2-0) converted more frequently to HER2-low than HER2-null (51.2% vs. 30.6%, p=0.045). This difference remained statistically significant in the multivariable logistic regression model. In the full 517-patient contextual cohort, HER2 expression gain in recurrent/metastatic lesions was independently associated with poorer post-recurrence survival (PRS) (adjusted hazard ratio [HR], 1.74; p=0.009). In the 488-patient primary cohort, conversion from HER2-0 to HER2-low was also associated with poorer PRS (adjusted HR, 2.18; p < 0.001). The broader HER2 expression evolution in the full 517‑patient cohort and the primary 488‑patient refined HER2 cohort was consistent with the core finding from the 92‑patient HER2‑0 analytic cohort and supported its biological plausibility.
Conclusion HER2-ultralow shows distinct evolution and high HER2-low conversion potential, affecting ADC eligibility. Routine HER2-0 subclassification and metastatic HER2 reassessment appear clinically useful and warrant prospective validation.
Purpose With longer survivals in advanced cancer, the need for supportive care is increasing. However, in Korea, these services remain limited, and many patients rely on long-term care hospitals. We investigated the supportive care experiences of patients with advanced cancer and their caregivers, and preferred place of care (pPOC) by performance status (PS).
Materials and Methods A cross-sectional survey was conducted at a tertiary hospital in Seoul, Korea, targeting patients hospitalized only for supportive care and their caregivers. PS was assessed using the Eastern Cooperative Oncology Group scale (good [0-1] or poor [2-4]). Hospital and home care experiences and pPOC were compared by PS. Logistic regression analysis was used to identify factors associated with pPOC.
Results This study included 200 participants (117 patients, 83 caregivers). Among patients, 72% had good PS and 28% had poor PS. Main reasons for hospitalization were symptom control (51.5%), assistance with daily living (36.5%), and device or wound management (22.5%). Overall, 60.5% of participants reported discomfort during hospitalization, mostly related to hospital life, and 34.5% noted that care was insufficient at home, particularly those in the poor PS group (27.1% vs. 53.6%). Concern about emergencies was the most common home-care difficulty. Despite these challenges, 60% of participants chose home as their future pPOC, with no significant differences by PS or other demographic/clinical factors.
Conclusion Although most patients with advanced cancer and their caregivers preferred home for supportive care, many relied on hospitals. Structured home-based medical care programs are urgently required in South Korea.
Minkyu Jung, Soo Hyun Park, Hyoyoung Kim, Youhyun Kim, Un-Jung Yun, Jiwoo Hwang, Hyo Song Kim, Choong-kun Lee, Hyunki Kim, Chung Lee, Dong-Hoe Koo, Hei-Cheul Jeung, Dae Young Zang, Eun-Kee Song, Sun Young Rha
Received December 10, 2025 Accepted May 1, 2026 Published online May 4, 2026
Purpose Pemigatinib is a selective inhibitor of fibroblast growth factor receptors (FGFRs) 1-3 with demonstrated activity in tumors harboring FGFR2 fusions or amplifications. This phase Ib/II trial assessed the efficacy and safety of pemigatinib in combination with paclitaxel in patients with recurrent or advanced gastric cancer exhibiting fibroblast growth factors (FGFs)/FGFRs alterations.
Materials and Methods Patients with gastric cancer harboring FGFs/FGFRs aberrations who experienced progression following firstline therapy were enrolled. The phase Ib component established the recommended phase II dose (RP2D); the phase II component evaluated clinical efficacy.
Results Twelve patients were enrolled. The RP2D was determined as pemigatinib 13.5 mg/day (days 1-21) plus paclitaxel 80 mg/m2 (days 1, 8, and 15) every 4 weeks. Median progression-free and overall survival were 4.4 and 10.5 months, respectively. Patients with FGFR2 amplification (n=6) exhibited prolonged progression-free survival (6.5 vs. 3.5 months, p=0.049), while overall survival did not differ significantly. The objective response and disease control rates were 33.3% and 91.7%, respectively. The most frequent treatment-related adverse events were neutropenia (83.3%, grade ≥ 3: 58.3%) and hyperphosphatemia (83.3%, grade ≥ 3: 33.3%).
Conclusion Pemigatinib plus paclitaxel demonstrated antitumor activity with an acceptable safety profile in FGFR2-amplified gastric cancer. Further investigation is warranted to elucidate resistance mechanisms and validate these findings in larger cohorts.
Kyong-Min Kang, Ho Yung Lee, Hong-min Ahn, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Dong Woon Lee, Sung Chan Park, Jae Hwan Oh, Min Jung Kim, Ji Won Park, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park
Received November 27, 2025 Accepted April 30, 2026 Published online May 4, 2026
Purpose The role of adjuvant chemotherapy (ACT) in pathologic T3N0 (pT3N0) rectal cancer, which has a favorable prognosis, remains controversial because high-risk groups for recurrence are not well defined. This study investigated prognostic factors for survival in this patient group and evaluated the benefit of ACT based on these factors.
Materials and Methods This retrospective study analyzed 352 patients with pT3N0 rectal cancer who underwent upfront radical surgery at three referral hospitals between November 2003 and December 2020. A multivariable Cox regression model was used to identify the prognostic factors for 5-year recurrence-free survival (RFS). Patients were categorized as high or low risk based on these factors, and survival outcomes were compared between those who received ACT and those who did not, using the log-rank test.
Results Median follow-up was 52.8 months. One hundred ninety-three patients (54.8%) received ACT. Multivariable analysis revealed that ACT, circumferential resection margin (CRM) ≤ 2 mm, vascular invasion, and perineural invasion were independent predictors of 5-year RFS. In patients with ≥ 1 risk factor, ACT significantly improved RFS (92.5% vs. 72.8%; hazard ratio [HR], 0.247; 95% confidence interval [CI], 0.090 to 0.683; p < 0.01). In those without risk factors, no significant benefit was observed (98.0% vs. 91.6%; HR, 0.272; 95% CI, 0.057 to 1.313; p=0.082).
Conclusion This study identified CRM ≤ 2 mm, vascular invasion, and perineural invasion as high-risk features for recurrence in pT3N0 rectal cancer. ACT improved RFS only in patients with these features. While these findings support risk-based ACT administration in this patient population, further validation of our risk stratification system is needed.
Purpose This study aimed to compare the efficacy and safety of concurrent chemoradiotherapy (CCRT) with or without induction chemoimmunotherapy in unresectable esophageal squamous cell carcinoma (ESCC).
Materials and Methods The study included patients with unresectable ESCC who received CCRT with or without induction chemoimmunotherapy at three cancer centers. Patients receiving concurrent immunotherapy were excluded. Propensity score matching (PSM) balanced baseline characteristics between groups.
Results A total of 519 patients were included. After PSM, 183 patients per group were selected. Induction chemoimmunotherapy significantly improved overall survival (OS) and progression-free survival (PFS) compared to CCRT alone, consistently. The median OS for the CCRT and induction chemoimmunotherapy groups were 29.9 months (95% confidence interval [CI], 18.8 to 41.0) and not reached (hazard ratio [HR], 0.57; 95% CI, 0.42 to 0.77; p < 0.001). The median PFS was 17.6 months (interquartile range [IQR], 13.7 to 21.4) versus 30.6 months (IQR, 17.3 to 43.8) (HR, 0.66; 95% CI, 0.51 to 0.86; p=0.002). Responders to the induction chemoimmunotherapy had significantly better OS (HR, 0.22; 95% CI, 0.14 to 0.36; p < 0.001) than nonresponders. Subgroup analysis showed that radiation dose escalation or consolidation immunotherapy did not further improve survival in the induction chemoimmunotherapy group.
Conclusion The addition of induction chemoimmunotherapy to CCRT was associated with improved survival in patients with locally advanced unresectable ESCC, particularly in responders to induction chemoimmunotherapy, with acceptable toxicity. These findings warrant confirmation in prospective randomized trials.
Citations
Citations to this article as recorded by
Induction Chemoimmunotherapy Versus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study Jiayue Liu, Wei Deng, Xin Dong, Yuting Zhao, Leilei Jiang, Liuhua Long, Yue Teng, Dan Yang, Jiayi Yu, Xiao Chang, Huiming Yu, Anhui Shi, Weihu Wang, Rong Yu Journal of Clinical Medicine.2026; 15(20): 8121. CrossRef
Major advances in the management of human epidermal growth factor receptor 2 (HER2)–positive (HER2+) metastatic breast cancer (MBC) have been achieved through treatment intensification with novel HER2-targeted agents and combination strategies, resulting in substantial survival gains. However, indefinite exposure to systemic therapy imposes cumulative toxicity, financial strain, and quality-of-life burdens. In contrast, the concept of treatment de-escalation, aimed at maintaining disease control with less intensive therapy, has only recently emerged as a complementary paradigm. This review highlights two evolving avenues of treatment de-escalation. First, in hormone receptor–positive/HER2+ disease, randomized trials have demonstrated that combining HER2 blockade with endocrine therapy and cyclin-dependent kinase 4 and 6 inhibitors can overcome endocrine resistance, offering a chemotherapy-sparing approach with outcomes comparable to chemotherapy or antibody-drug conjugates. Second, in long-term responders, retrospective analyses and ongoing prospective trials are evaluating whether discontinuation of prolonged maintenance HER2 therapy can safely reduce treatment burden while preserving disease control, with the added potential for effective rechallenge upon relapse. Together, these developments suggest that treatment de-escalation represents a rational and necessary treatment strategy. Future progress will depend on biomarker-driven patient selection and prospective validation. Redefining success in HER2+ MBC to include not only survival but also quality of life and sustainability represents an important step toward patient-centered cancer care.
Citations
Citations to this article as recorded by
Advancing therapies for HER2-positive metastatic breast cancer: Navigating a wealth of treatment options Michela Palleschi, Alessandro Viansone, Filippo Merloni, Caterina Gianni, Alberto Farolfi, Giulia Miserocchi, Marita Mariotti, Giandomenico Di Menna, Olga Serra, Chiara Casadei, Simone Sabbioni, Andrea Carlini, Daniela Montanari, Marianna Sirico, Francesc Cancer Treatment Reviews.2026; 150: 103218. CrossRef
Purpose This study aimed to assess lymph node status in patients undergoing additional surgery after endoscopic resection to evaluate the need for complete mesocolic excision with central vascular ligation for clinically suspected early-stage right-sided colon cancer.
Materials and Methods This retrospective study, conducted at a single institution using a prospectively collected database, comprised patients who underwent additional surgery following endoscopic intervention between May 2003 and March 2022. The primary outcomes were the rate and location of lymph node metastases, including peritumoral, pericolic, and superior mesenteric lymph nodes. The secondary outcome was recurrence-free survival.
Results Among 119 patients, pathological examination identified five (4.2%) with Tis requiring surgery owing to uncheckable margins or tumor depth, 106 (89.1%) with stage T1 tumors, and eight (6.7%) with stage T2 tumors. The nodal stage was N0 in 107 patients (89.9%) and N1 in 12 patients (10.1%). The mean number of harvested lymph nodes was 43.1, including 7.6±6.9 peritumoral, 31.5±14.4 pericolic, and 4.0±3.8 superior mesenteric nodes. All metastatic lymph nodes were in the peritumoral and pericolic regions. At a mean follow-up of 48.2 months, recurrence occurred in one patient (0.8%), who developed liver metastases 24 months postoperatively.
Conclusion For patients with clinically suspected early-stage right-sided colon cancer who initially underwent endoscopic resection, the risk of superior mesenteric node metastases is very low. D2 lymph node dissection alone may be sufficient rather than routine application of complete mesocolic excision with central vascular ligation, which might be reconsidered in these patients.
Eun Hye Park, Kyu-Won Jung, Seo Hyun Choi, Nam Ju Park, Mee Joo Kang, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Kui Son Choi, Han-Kwang Yang, The Community of Population-Based Regional Cancer Registries
Cancer Res Treat. 2026;58(2):349-367. Published online March 23, 2026
Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2023, with international comparisons.
Materials and Methods Cancer incidence, survival, and prevalence rates were calculated using the Korea National Cancer Incidence Database (1999-2023), with survival follow-up until December 31, 2024. Mortality data were obtained from the Ministry of Data and Statistics, while international comparisons were based on GLOBOCAN data.
Results In 2023, 288,613 newly diagnosed cancer cases (age-standardized rate [ASR], 288.6 per 100,000) and 85,271 deaths from cancer (ASR, 64.3 per 100,000) were reported. Among the incident cases, 145,452 (50.4%) were aged 65 years or older. Prostate cancer became the most common cancer among men for the first time. The proportion of localized-stage cancers increased from 45.6% in 2005 to 51.8% in 2023. Korea had the lowest cancer mortality among countries with similar incidence rates and the lowest mortality-to-incidence ratios for stomach, colorectal, and breast cancer. The 5-year relative survival rate (2019-2023) was 73.7% overall and 92.7% for localized-stage cancers. Over 2.73 million prevalent cases were identified in 2023, representing 5.3% of the Korean population.
Conclusion These findings indicate that Korea’s cancer control efforts have contributed to early detection and improved survival outcomes. As Korea enters a super-aged society in 2025, cancer burden will continue to increase, requiring sustained and adaptive cancer control strategies.
Citations
Citations to this article as recorded by
Population ageing, caregiving, and the economic burden of cancer in South Korea, 2011–2020 Jang Won Lee, Min Kyung Hyun, Dal-Lae Jin, Minkyung Jo, Jinah Sim, Ru-Gyeom Lee, Young Ae Kim Health Policy and Technology.2027; 16(1): 101324. CrossRef
Epidemiological Trends, Inter-Cancer Correlations, and Incidence Projections for 61 Cancer Types in Korea, 1999–2028: A Nationwide Population-Based Study Hyeran Jung, Minsun Jung Cancers.2026; 18(14): 2341. CrossRef
Single-port robotic areolar surgery for thyroid and neck procedures: a 3-year, 500-case single-surgeon experience using the da-Vinci SP system Myeong Ho Shin, Gi Tae Kim, Seung Hwan Lim, Jin Wook Yi Updates in Surgery.2026;[Epub] CrossRef
Shifting Cancer Landscapes in Korea: Divergent Incidence Trajectories, Sex-Specific Burdens, and Projected Case Counts for 24 Major Cancer Types from 1999 to 2023, with Forecasts to 2030 Hyeran Jung, Minsun Jung Current Oncology.2026; 33(8): 444. CrossRef
Emerging cancer incidence trends in younger generations: age-specific trends and birth cohort effects from 25 years of Korean Cancer Registry data Bohyun Park, Hye Ah Lee, Bomi Park, Hyesook Park Cancer Epidemiology.2026; 104: 103209. CrossRef
Diagnostic Performance of Post-Treatment F-18 FDG PET/CT for Detecting Recurrent Cervical Cancer Choon-Young Kim, Sang-Woo Lee, Gun Oh Chong, Jong Mi Kim, Yoon Hee Lee, Chae Moon Hong, Shin Young Jeong Diagnostics.2026; 16(17): 2691. CrossRef
Within-Region Versus Out-of-Region Cancer Care: Healthcare Patterns and Clinical Outcomes in South Korea Woo-Ri Lee, Jinsoo Shin, Junghwa Kim, Kyu-Tae Han Cancers.2026; 18(17): 2879. CrossRef
Cancer Stigma, Distress, and Cancer Coping in Relation to the Quality of Life Among Patients with Lung Cancer: A Cross-Sectional Study Ji-Yeon Pyo, Seungkyoung Yang Healthcare.2026; 14(19): 3163. CrossRef
Associations of Symptom Experience, Health Literacy, and Social Support with Self-Care Agency Among Older Colorectal Cancer Survivors Hyedan Kim, Eunsook Wi, Hyekyung Kim Asian Oncology Nursing.2026; 26(3): 157. CrossRef
Factors Associated with Hospice Service Use among Decedents with Solid Cancers: A Population-Based Study Using the National Health Insurance Service–National Sample Cohort Ji-Young Jeong, Hee-Ju Ji The Korean Journal of Health Service Management.2026; 20(3): 29. CrossRef
ADAM10 as a Potential Biomarker in Non-Small Cell Lung Cancer and Its Major Histologic Subtypes Sae-Beaul Kim, Yun-Jeong Kim, Yunha Lee, Ji-Hun An, Min-Gyeol Kim, Jin Lee, Ye-Rin Jung, Jun-Chae Lee, Jae-Ho Lee, Taehun Kim Medicina.2026; 62(10): 2015. CrossRef
Diffuse GLUT1 Expression Is Associated with Reduced Cytoplasmic p-YAP Immunoreactivity in Endometrioid Endometrial Carcinoma Dae Hyun Song, Hyen Chul Jo, Chohee Kim, Juseok Yang, In Ae Cho, Ji Eun Park, Jong Chul Baek Medicina.2026; 62(11): 2085. CrossRef
Purpose This study aimed to project cancer incidence and mortality for 2026 to estimate Korea’s current cancer burden.
Materials and Methods Cancer incidence data from 1999 to 2023 were obtained from the Korea National Cancer Incidence Database, while cancer mortality data from 1993 to 2024 were acquired from the Ministry of Data and Statistics. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and then by the projected age-specific rates by the anticipated age-specific population for 2026. A joinpoint regression model was applied to identify significant changes in trends, using only the most recent trend data for predictions.
Results A total of 308,876 new cancer cases and 86,317 cancer deaths are expected in Korea in 2026. The most commonly diagnosed cancer is projected to be thyroid cancer, followed by the colorectal, lung, breast, prostate and stomach cancers. These six cancers are expected to account for 63.5% of all newly diagnosed cancers. Lung cancer is expected to be the leading cause of cancer-related deaths, followed by liver, colorectal, pancreatic, gallbladder, and stomach cancers, together comprising 65.9% of all cancer deaths.
Conclusion Korea’s cancer burden continues to shift toward malignancies prevalent in older populations. The sustained increase in prostate cancer among men and the rising mortality impact of pancreatic cancer reflect structural changes in the national cancer profile amid rapid population aging.
Citations
Citations to this article as recorded by
Longitudinal Analysis of Testicular Cancer Patient Volume and Co-Occurring Urological Conditions Using the Health Insurance Review and Assessment (HIRA) Database in South Korea (2020–2024) with Exploratory Forecasts for 2026–2028 Hyeran Jung, Minsun Jung Cancers.2026; 18(14): 2325. CrossRef
Purpose Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. CD103+ tissue-resident memory T cells are crucial for anti-tumor immunity in TNBC. We investigated whether their spatial interactions with other T-cells influence clinical outcomes, particularly following neoadjuvant chemotherapy (NAC).
Materials and Methods This retrospective study analyzed 182 TNBC patients (98 NAC-treated, 84 non-NAC). Using Opal multiplex immunohistochemistry data and the Spatial Image Analysis of Tissues R package, we analyzed spatial interactions between CD103+ cells and other T-cell subsets (CD45RO, CD8, CD4, and programmed cell death 1) in central/peripheral tumor regions. Normalized mixing score (NMS) quantified spatial interactions.
Results NMS-based clustering revealed two distinct CD103+ cell interaction patterns—cluster 1 (low NMS) characterized by weaker and cluster 2 (high NMS) by stronger spatial interactions between CD103+ and other T-cell subsets. In the NAC group, cluster 2 in the tumor periphery was associated with lower pathologic stage (p=0.002), higher stromal tumor-infiltrating lymphocyte level (p=0.031), and significantly improved recurrence-free survival (p=0.028) and overall survival (p=0.018) compared to cluster 1. Central tumor region clustering patterns had no association with prognosis. No significant survival-related differences were observed in the non-NAC group according to NMS-based clustering.
Conclusion Spatial interaction patterns between CD103+ and other T-cell subsets in the tumor periphery influence clinical outcomes in NAC-treated TNBC patients. Analysing such spatial relationships between T cells, rather than their presence alone, may provide additional prognostic information for patients undergoing NAC.
Citations
Citations to this article as recorded by
Spatial immune biomarkers in triple-negative breast cancer: emerging evidence, technology trade-offs, and barriers to clinical translation Liuhai Zeng, Wei Lin, Shihang Xue, Minzhi Chen, Haiyan Wu Frontiers in Immunology.2026;[Epub] CrossRef